"Relapse" from_date:2012

Ublituximab for treating relapsing multiple sclerosis Ublituximab for treating relapsing multiple sclerosis Technology appraisal guidance Published: 18 December 2024 www.nice.org.uk/guidance/ta1025 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ublituximab for treating relapsing multiple sclerosis (TA1025)© NICE 2024. All rights reserved. Subject to Notice of rights ( 2of 9 Contents 1 Recommendations

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments Technology appraisal guidance Published: 11 December 2024 www.nice.org.uk/guidance/ta1023 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or moretreatments (TA1023)© NICE 2024. All rights reserved. Subject to Notice

Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) Technology appraisal guidance Published: 22 January 2025 www.nice.org.uk/guidance/ta1032 © NICE 2025. All rights reserved. Subject cancer (terminated appraisal) (TA1032)© NICE 2025. All rights reserved. Subject to Notice of rights ( 2of 3 Advice NICE is unable to make a recommendation about the use in the NHS of niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine has confirmed that it does not intend to make

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) Technology appraisal guidance Published: 27 March 2024 www.nice.org.uk/guidance/ta960 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions #notice-of-rights).Contents Advice ................................................................................................................................3 Information ..................................................................................................................................3 Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders(terminated

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25?years and under Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under Technology appraisal guidance Published: 15 May 2024 www.nice.org.uk/guidance/ta975 © NICE 2024. All rights reserved. Subject to Notice of rights discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia inpeople 25

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over Technology appraisal guidance Published: 1 May 2024 www.nice.org.uk/guidance/ta967 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3years and over (TA967)© NICE 2024. All rights

Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments Technology appraisal guidance Published: 8 May 2024 www.nice.org.uk/guidance/ta970 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4or more treatments (TA970)© NICE 2024. All rights

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) Technology appraisal guidance Published: 10 July 2024 www.nice.org.uk/guidance/ta987 © NICE 2024. All rights reserved. Subject to Notice of rights ( Advice ................................................................................................................................3 Information ..................................................................................................................................3 Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma Technology appraisal guidance Published: 3 September 2018 www.nice.org.uk/guidance/ta540 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility Your and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of27Contents Contents 1 Recommendations

Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments Technology appraisal guidance Published: 31 January 2024 www.nice.org.uk/guidance/ta947 recommendations wherever possible. Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphomaand high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)© NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of21Contents 1 Recommendations

Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment Health technology evaluation Published: 25 March 2024 www.nice.org.uk/guidance/hte17 © NICE 2024. All rights reserved. Subject health technologies to help manage symptoms of psychosis and prevent relapse inadults and young people: early value assessment (HTE17)© NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of18Contents 1 Recommendations

Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Technology appraisal guidance Published: 25 April 2024 www.nice.org.uk/guidance/ta968 © NICE 2024. All rights reserved. Subject to Notice of rights ( Advice ................................................................................................................................3 Information ..................................................................................................................................3 Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiplemyeloma (terminated appraisal) (TA968)© NICE 2024. All rights reserved. Subject to Notice of rights ( 2of 3 Advice NICE is unable to make a recommendation about the use

Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) Technology appraisal guidance Published: 29 May 2024 www.nice.org.uk/guidance/ta978 © NICE 2024. All rights reserved. Subject to Notice of rights ( Advice ................................................................................................................................3 Information ..................................................................................................................................3 Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell

Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments Technology appraisal guidance Published: 6 March 2024 www.nice.org.uk/guidance/ta954 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Epcoritamab for treating relapsed or refractory

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer Technology appraisal guidance Published: 7 February 2024 www.nice.org.uk/guidance/ta951 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer(TA951)© NICE 2024

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer Technology appraisal guidance Published: 17 September 2024 www.nice.org.uk/guidance/ta1007 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tubeor peritoneal cancer (TA1007)© NICE 2024. All

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments Technology appraisal guidance Published: 13 November 2024 www.nice.org.uk/guidance/ta1015 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or moretreatments (TA1015)© NICE 2024. All rights reserved. Subject to Notice

Polatuzumab vedotin (relapsed or refractory DLBCL) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 5 of the dossier assessment Polatuzumab Vedotin (Kombination mit Bendamustin und Rituximab, rezidivierendes oder refraktäres DLBCL) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Polatuzumab Vedotin (combination with bendamustine and rituximab, relapsed or refractory DLBCL) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-140 Version: 1.0 Status: 26 Mar 2024 DOI: 10.60584/A23-140_en Extract of dossier assessment A23-140 Version 1.0 Polatuzumab Vedotin ( combination

Relapse Prevention in compulsory care for patients with substance abuse disorder ConsentDetailsAboutThis website uses cookiesWe use cookies to facilitate your visit, provide social media features and analyze our traffic to continuously improve the website. Read more about cookiesCustomizeAllow all cookiesPowered by Cookiebot by UsercentricsHoppa till textinnehållet Find on page MenuSearchRelapse Prevention in compulsory care for patients with substance abuse disorderRelapse Prevention is a treatment programme focusing on harmful substance use. The programme emphasizes how to identify and manage situations that increase the risk of relapse. Reading time approx. 13 minutes Published: March 24, 2023 Publication type: SBU Enquiry Service Share: QuestionWhat scientific studies have

Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) Technology appraisal guidance Published: 16 February 2023 www.nice.org.uk/guidance/ta869 © NICE 2023. All rights reserved. Subject to Notice of rights (https ://www.nice.org.uk/terms-and-conditions#notice-of-rights).Contents Advice ................................................................................................................................3 Information ..................................................................................................................................3 Teclistamab for treating relapsed or refractory multiple myeloma